摘要:
We disclose GPR26 G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding GPR26 polypeptide are also disclosed. The GPR26 receptor is useful in the diagnosis and therapy of mental illness.
摘要翻译:我们公开了包含SEQ ID NO:1所示的氨基酸序列的GPR26G-蛋白偶联受体(GPCR)多肽。 3或SEQ ID NO:5,及其同源物,变体和衍生物。 还公开了能够编码GPR26多肽的核酸。 GPR26受体可用于精神疾病的诊断和治疗。
摘要:
VDCC γ-8 polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3, SEQ ID NO. 5 or SEQ ID NO: 7, and homologues, variants and derivatives thereof are provided. Nucleic acids capable of encoding VDCC γ-8 polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID NO. 4 or SEQ ID NO: 6. These polypeptides and polynucleotides are implicated in mental illness and are useful in screening for therapeutic agents useful in treating mental illness.
摘要翻译:包含SEQ ID NO:1所示氨基酸序列的VDCCγ-8多肽。 3,SEQ ID NO: 5或SEQ ID NO:7,并提供其同系物,变体和衍生物。 还公开了能够编码VDCCγ-8多肽的核酸,特别是包含SEQ ID No.1,SEQ ID No.2,SEQ ID NO:1所示的核酸序列的核酸。 4或SEQ ID NO:6。这些多肽和多核苷酸涉及精神疾病,并且可用于筛选用于治疗精神疾病的治疗剂。
摘要:
We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a GPR86 associated disease, in particular inflammatory disease or pain, the method comprising determining whether a candidate molecule is an agonist or antagonist of GPR86 polypeptide, in which the GPR86 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5 or SEQ ID NO: 7, a fragment thereof or a sequence which is at least 90% identical thereto.
摘要翻译:我们描述了鉴定适于治疗,预防或减轻GPR86相关疾病,特别是炎性疾病或疼痛的分子的方法,该方法包括确定候选分子是否是GPR86多肽的激动剂或拮抗剂,其中GPR86 多肽包含SEQ ID NO:3或SEQ ID NO:5或SEQ ID NO:7所示的氨基酸序列,其片段或与其至少90%相同的序列。
摘要:
The present invention relates to novel functions of a known receptor. In particular, the invention relates to the use of a sphingosylphosphorylcholine receptor and/or ligands thereof in the manipulation of the neuronal and limbic systems and diagnosis and treatment of pain.
摘要:
The present invention relates to novel functions of a known receptor. In particular, the invention relates to the use of a galanin-like receptor and/or ligands thereof in the manipulation of the pituitary hormonal axis and reproductive systems.
摘要:
We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, or a sequence which is at least 90% identical thereto.
摘要翻译:我们描述了鉴定适合于治疗,预防或减轻Gpr100相关疾病,特别是糖尿病和肥胖症的分子的方法,该方法包括确定候选分子是否是Gpr100多肽的激动剂或拮抗剂,其中Gpr100多肽 包含SEQ ID NO:3或SEQ ID NO:5所示的氨基酸序列,或与其至少90%相同的序列。
摘要:
We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, or a sequence which is at least 90% identical thereto.
摘要翻译:我们描述了鉴定适合于治疗,预防或减轻Gpr100相关疾病,特别是糖尿病和肥胖症的分子的方法,该方法包括确定候选分子是否是Gpr100多肽的激动剂或拮抗剂,其中Gpr100多肽 包含SEQ ID NO:3或SEQ ID NO:5所示的氨基酸序列,或与其至少90%相同的序列。
摘要:
We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a GPR86 associated disease, in particular inflammatory disease or pain, the method comprising determining whether a candidate molecule is an agonist or antagonist of GPR86 polypeptide, in which the GPR86 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5 or SEQ ID NO: 7, a fragment thereof or a sequence which is at least 90% identical thereto.
摘要翻译:我们描述了鉴定适于治疗,预防或减轻GPR86相关疾病,特别是炎性疾病或疼痛的分子的方法,该方法包括确定候选分子是否是GPR86多肽的激动剂或拮抗剂,其中GPR86 多肽包含SEQ ID NO:3或SEQ ID NO:5或SEQ ID NO:7所示的氨基酸序列,其片段或与其至少90%相同的序列。
摘要:
We disclose a method of treating or preventing a disease selected from the group consisting of: a bladder disease, a bladder disorder, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, including overflow and urge incontinence, urinary urge, cystitis, including interstitial cystitis and overactive bladder.
摘要:
Methods and systems for performing analytical reactions under reduced or non-oxygen conditions, where such reactions are potentially subject to damaging effects of oxygen, including particularly fluorescent based detection methods where fluorescent species may be prone to generation of reactive oxygen species.